Cardisure Pimobendan is a complete analog of Vetmedin, Heartmedin – 100 Tabs
The active ingredient is Pimobendan.
Benefits:
The drug is designed to treat and support the vascular system and heart in dogs.
The level of effectiveness of the drug is high
Regular use increases the activity of the pet, reducing shortness of breath and whooping cough.
The drug can be used only after consultation and recommendation of a veterinarian.
With proper use of the drug Kardishur pet will be able to feel better and lead a full life.
WARNING!!! Before using the drug should consult a veterinarian. The drug should be taken after reading the instructions for use.
Instructions for use of the drug Cardishur (Cardisure)
Cardishur (Cardisure) is a complete analogue of Vetmedin 100 capsules, only in tablet form.
Apples for oral use
Active substance:
1 tablet (weighing 450/900/1800 mg) contains the active substance: pimobendan – 2.5 / 5/10 mg. Excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, natural meat flavor OHLY.
Pimobendan is a benzimidazole-pyridazinone derivative, an unsympathomimetic, non-glycosidic inotropic substance with potent vasodilating properties. Has a stimulating myocardial effect through a dual mechanism of action: increases the calcium sensitivity of cardiac myofilaments and inhibits phosphodiesterase (type III). Pimbendan has a vasodilating effect by inhibiting the activity of phosphodiesterase III. When pimobendan was used in combination with furosemide for heart valve failure, it was shown that the drug improves the quality and prolongs the life expectancy of dogs treated.
Indications for use:
For the treatment of dogs with congestive heart failure due to dilated cardiomyopathy or valvular insufficiency (regurgitation of mitral and / or tricuspid valves).
Contraindications
Do not use in hypertrophic cardiomyopathies or clinical conditions when cardiac output cannot be increased for functional or anatomical reasons (eg aortic stenosis).
Because the main metabolism of pimobendan is in the liver, the drug should not be used in dogs with severe hepatic impairment.
Side effects
Moderately positive chronotropic effects and nausea may occur rarely. However, these effects are dose-dependent and can be avoided by reducing the dose of the drug.
Temporary diarrhea, anorexia, or lethargy have been reported rarely.
Rarely, chronic mitral valve insufficiency has been reported during chronic treatment with pimobendan in dogs with mitral regurgitation.
Signs of primary hemostasis (mucosal petechiae, subcutaneous haemorrhage) have been reported very rarely during treatment, although it is not clear what pimobendan causes. These symptoms disappear after discontinuation of treatment.
The frequency of adverse reactions is determined using the following model:
– very common (more than 1 in 10 animals experiencing adverse reactions during one treatment);
– frequent (more than 1, but less than 10 per 100 animals);
– infrequent (more than 1, but less than 10 per 1000 animals);
– rarely (more than 1, but less than 10 per 10,000 animals);
– very rare (less than 1 animal in 10,000 animals.
Special precautions for
use Accidental ingestion of the tablets should be kept out of the reach of dogs Laboratory studies in rat tissues have shown that, depending on the dose, pimobendan increases the release of insulin (due to glucose) from pancreatic Ξ²-cells. diabetes, blood glucose levels should be closely monitored.
To use the drug for the treatment of dilated cardiomyopathy in the preclinical stage (asymptomatic with increasing end-systolic and end-diastolic diameter of the left ventricle) should be diagnosed by a comprehensive cardiac examination (including echocardiography and possibly Holter monitoring).
For the use of the drug for the treatment of myxomatous mitral heart disease in the preclinical stage (stage B2, according to the ACVIM consensus: asymptomatic course with mitral murmur β₯ 3/6 and cardiomegaly due to myxomatous mitral heart disease) should be diagnosed by comprehensive physical and cardiology which should include, if necessary, echocardiography or radiography.
Monitoring of cardiac function and morphology in animals receiving pimobendan is recommended.
The drug has not been studied in cases of asymptomatic dilated cardiomyopathy (DCMP) in Dobermans with atrial fibrillation or persistent ventricular tachycardia.
The drug has not been studied in cases of asymptomatic myxomatous mitral heart disease in dogs with significant supraventricular and / or ventricular tachyarrhythmias.
Use during pregnancy and lactation
Laboratory studies in rats and rabbits have shown no evidence of teratogenic or phytotoxic effects. However, these studies demonstrated matotonoxic and embryotoxic effects when used in high doses, and also showed that pimobendan is excreted in milk.
The safety of the drug in pregnant and lactating animals has not been evaluated. It is recommended to use the drug only in accordance with the benefit / risk assessment by the responsible veterinarian.
Interaction with other medicinal products and other forms of interaction
Pharmacological studies have not shown an interaction between the cardiac glycoside strophanthin and pimobendan.
Pimobendan-induced increase in heart rate is attenuated by the presence of the calcium antagonist verapamil and the Ξ²-antagonist propranolol.
Dosage and method of application
Do not exceed the recommended dose!
Prior to treatment, the animal’s body weight must be accurately determined to ensure proper dosing.
Tablets should be administered orally in the dose range from 0.2 mg to 0.6 mg of pimobendan per 1 kg of body weight divided into two doses per day.
The recommended daily dose is 0.5 mg of pimobendan per 1 kg of body weight. The dose should be divided into two doses of 1 tablet – in the morning and after about 12 hours. The maintenance dose should be individually adjusted by the responsible veterinarian taking into account the severity of the disease. The drug can be combined with a diuretic, such as furosemide.
To divide the tablet into quarters, place the tablet on a flat surface, with the score line facing up, hold one half of the tablet, and press your thumb on the center of the tablet.
Each dose should be given approximately one hour before feeding.
Overdose (symptoms, emergency procedures, antidotes)
In case of overdose, a positive chronotropic effect and vomiting may occur. In this situation, the dosage should be reduced and appropriate symptomatic treatment instituted.
With long-term use (6 months) of the dose in healthy dogs of the Beagle breed, which is 3 and 5 times higher than the recommended dose, mitral valve thickening and left ventricular hypertrophy were observed in some animals.
Special precautions for use by veterinary medicinal products to animals
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label.
Wash hands thoroughly after use.
Advice to doctors: Accidental ingestion of the drug, especially by a child, can lead to tachycardia, orthostatic hypotension, facial flushing and headache.
Main forms of incompatibility
Unknown.
Shelf life
2.5 years.
The shelf life of the divided tablets after the first opening of the blister is 3 days.
Special precautions for storage
Store at 5 to 30 Β° C in the manufacturer’s packaging.
Parts of the divided tablet should be stored in a blister for 3 days.
Packaging:
2.5 mg / 100 tablets
5 mg / 100 tablets
10 mg / 100 tablets
Manufacturer : Dechra Limited, Dechra Pharmaceuticals PLC, United Kingdom